Australian Participants in British Nuclear Tests and British Commonwealth Occupation Force (Treatment) (Modifications of the Repatriation Pharmaceutical Benefits Scheme) Instrument 2017

The instrument expresses a small set of legal concepts and relationships. Each concept is created, retained, or eliminated by discrete schedule items; the following list sets them out and cites where the instrument implements them.

• Scheme: The instrument defines "Scheme" as the Repatriation Pharmaceutical Benefits Scheme as modified by this instrument (Schedule 1, item 8). That means the instrument operates by amending the prior RPBS instrument and by asserting the modified instrument is the operative scheme for relevant purposes.
• Authorisation: The Scheme is expressly authorised by section 18 of the Act (Schedule 1, item 2). The making of the instrument itself relies on the Repatriation Commission’s authority under s 18 of the Act (clause 3).
• Eligible Person: The instrument aligns eligibility to the Act by redefining "Eligible Person" to mean an eligible person within the meaning of the Act (Schedule 1, item 4). This shifts the primary eligibility test to the Act’s definitions rather than to scheme-specific scaffolding.
• Community Pharmacists as suppliers: The instrument creates a short, explicit operative purpose in s 2A: "The Scheme enables Community Pharmacists to supply Pharmaceutical benefits to Eligible Persons" (Schedule 1, item 2A). The phrasing is permissive: it enables supply rather than prescribing exclusive supply channels or payment mechanisms within the text of this instrument.
• Repatriation Health Card ‑ For All Conditions: A succinct single-card definition is introduced: "Repatriation Health Card ‑ For All Conditions means an identification card, or written authorisation, provided to an Eligible Person in relation to treatment for all injuries or diseases" (Schedule 1, item 6). Other card types are deleted (Schedule 1, item 7).
• Terminology alignment: The instrument systematically removes references to "allowance" and substitutes "supplement" in s 23 to align terminology with the Act’s language (Schedule 1, items 20-25). It also adjusts cross-references, for example replacing "the Act" with "the National Health Act 1953" in subsection 16A(9) and changing "RPBS listed" to "RPBS Schedule listed" in s 17 (Schedule 1, items 13, 14).
• Transitional continuity: Section 2B provides that things started under the previous 2006 RPBS instrument but not finished by 1 July 2017 may be completed under the new Scheme as if they had been started under it (Schedule 1, item 2B). This preserves administrative continuity for in-progress matters.
• Repeal of prior instrument: The prior instrument named Repatriation Pharmaceutical Benefits Scheme (Australian Participants in British Nuclear Tests) 2006 is repealed in full (Schedule 2).

Mechanically, the instrument is compact: it primarily revises the Scheme's front-end definitions, authorisation statement, operational purpose clause, and terminology, and repeals the prior instrument. It does not, within the text provided, create a new funding mechanism, set prices or formularies, impose new compliance penalties, or alter specific benefit amounts. It instead creates an enabling structure that ties supply of pharmaceutical benefits to Eligible Persons (as defined in the Act) and retools the Scheme’s internal referents.

The instrument identifies a small set of actors and stakeholders by naming roles or by operation of the definitions it modifies.

• Eligible Persons: The primary recipients affected are "Eligible Persons", defined by reference to the Act (Schedule 1, item 4). The instrument does not restate the Act’s eligibility criteria; it imports them. Consequently the population affected is precisely those persons whom the Act treats as eligible for treatment relating to Australian participants in British nuclear tests and British Commonwealth Occupation Force treatment. The instrument therefore overlays the RPBS with the Act’s entitlement scope.
• Community Pharmacists: The instrument explicitly names Community Pharmacists and authorises that the Scheme "enables Community Pharmacists to supply Pharmaceutical benefits to Eligible Persons" (Schedule 1, item 2A). That places pharmacists at the point of supply under the Scheme.
• Repatriation Commission: The instrument is prepared by the Repatriation Commission; it is made under the Commission’s statutory authority in section 18 of the Act (clause 3). The Commission both decides to make the instrument and affixes its seal. The Commission is therefore the instrument-holder and administrator in the first instance.
• Minister for Veterans’ Affairs: The instrument is approved by the Minister (signed by Dan Tehan on 23 June 2017). Ministerial approval is part of the instrument’s administrative record and indicates an executive endorsement of the Commission’s action.
• Administrators of the Scheme and pharmacy systems: Although not named, the textual amendments imply administrative actors must update scheme materials, pharmacy claiming processes, verification procedures, forms, internal databases and any references in policy manuals to reflect the changed definitions, the removal of card types, and the replacement of "allowance" with "supplement" (see Schedule 1 items 3, 5, 6, 7, 20-25).
• Persons and lawyers using the prior 2006 instrument: Individuals and their advisers with matters "started" under the 2006 instrument but not finished by 1 July 2017 may be affected by the transitional provision allowing those matters to be completed under the new Scheme (Schedule 1, item 2B). Parties with ongoing administrative actions must account for this continuity rule.

Who pays is not set out in this instrument. The text enables Community Pharmacists to supply pharmaceutical benefits but does not, within the instrument, set payment rates, funding allocations or a claims mechanism. Any financial flows, claims submissions, reimbursement rates, or penalties for improper claims are outside the text provided and therefore must be found in the Act, in other primary legislation, or in administrative instruments not included here. The instrument’s repeal of the earlier 2006 RPBS instrument (Schedule 2) means that the prior instrument’s arrangements are displaced, subject to the transitional safety net in s 2B.

The instrument creates a small set of legal permissions and obligations by amendment rather than by introducing detailed operational duties. The following are the principal duties, permissions and rights that follow directly from the instrument text.

• Permission to supply pharmaceutical benefits: Section 2A states the Scheme enables Community Pharmacists to supply Pharmaceutical benefits to Eligible Persons (Schedule 1, item 2A). That is a positive enabling right conferred on pharmacists under the Scheme. The word "enables" suggests permission rather than an express duty to supply in every circumstance.
• Eligibility determination falls to the Act’s definition: By redefining "Eligible Person" as an eligible person within the meaning of the Act (Schedule 1, item 4), the instrument imports the Act’s eligibility criteria. The practical duty for administrators and pharmacists will be to verify eligibility in line with the Act (although the instrument does not re-state verification procedures).
• Identification and authorisation requirement: The new definition of Repatriation Health Card ‑ For All Conditions identifies an eligible person’s identification or written authorisation for treatment for all injuries or diseases (Schedule 1, item 6). That creates a functional right for the holder to rely on the card or written authorisation as proof of entitlement, and an implied duty on the supplier to accept such verification for the supply of benefits. The instrument also removes other card categories, so the Repatriation Health Card ‑ For All Conditions becomes the primary identification construct under the modified Scheme (Schedule 1, item 7).
• Continuity duty for pending matters: Section 2B provides that things started under the 2006 instrument may be finished under this Scheme as if started under it (Schedule 1, item 2B). The effect is to oblige administrators to allow completion of in-progress matters under the modified Scheme, preventing abrupt termination of ongoing applications or processes.
• Terminology and reference updating: The instrument requires (as a legal fact) that prior references to allowances be read as supplements in specific contexts, for example in s 23 where "allowance" is replaced by "supplement" (Schedule 1, items 20-25). Administrators updating documentation must therefore treat references as replaced where the instrument makes the substitution.
• Removal of prior scheme constructs: The omission of several definitions and Part 5A (Schedule 1, items 3, 5, 7, 9, 11, 26) changes what duties or rights are articulated in the scheme instrument. Where the instrument omits a prior term, any duties or rights that depended on that term in the prior instrument will need to be located in the Act or in other instruments. That shifts a compliance duty onto administrators and counsel to map old rights to their new legal home.

The instrument does not set out explicit enforcement mechanisms, penalties, claim lodgement procedures, pricing, or reimbursement processes within its text. Duties that are normally operational,such as how pharmacists lodge claims, what records must be retained, or inspections by administrators,are not created or detailed here. Those operational duties will be located in the Act, in the National Health Act 1953 where cross-references are made (Schedule 1, item 13), or in other administrative instruments. The instrument’s substantive effect is to reconfigure who is entitled and who may supply benefits rather than to prescribe detailed procedural obligations.

The instrument contains no express penalty clauses or enforcement provisions within its own text. It performs definitional and structural changes to the Scheme and leaves enforcement to other legislative sources. The following points flow from the text and its cross-references.

• No penalty provisions in instrument text: Review of the instrument shows no new civil or criminal penalty provisions are created. The instrument focuses on authorisation, definitions and terminology substitutions (Schedule 1; Schedule 2). Therefore the instrument itself does not prescribe sanctions for non-compliance with Scheme rules.
• Enforcement will be under enabling statutes: The Scheme is authorised by section 18 of the Act (Schedule 1, item 2), and the instrument changes a cross-reference in subsection 16A(9) to the National Health Act 1953 (Schedule 1, item 13). This indicates that any penal or enforcement regime relevant to Scheme administration is to be found in the parent statute (the Act), in the National Health Act 1953 as it applies, or in administrative rules or instruments that implement claiming and compliance procedures.
• Administrator-level enforcement: The instrument was prepared and sealed by the Repatriation Commission and approved by the Minister for Veterans’ Affairs (prefatory material). In practice, enforcement of Scheme rules, claim adjudication and recovery of incorrect payments, if any, would ordinarily be managed by the Commission under statutory authorities provided elsewhere. Those authorities are not re-stated here.
• Indirect compliance consequences: The instrument changes key definitions and deletes prior terms. That can create indirect enforcement consequences. For example, replacing "allowance" with "supplement" in s 23 (Schedule 1, items 20-25) may affect eligibility for payments linked elsewhere to the former terminology. Any recovery or enforcement action based on such eligibility would be pursued under whatever statutory or administrative recovery mechanisms apply to repatriation supplements or pharmaceutical supplements in the Act or related instruments.
• Transitional protection from abrupt enforcement: Section 2B preserves the ability to finish matters started under the old Scheme (Schedule 1, item 2B). That reduces the risk that a party will be exposed to an enforcement action or loss because of an administrative transition, at least for matters begun before 1 July 2017.

In short, the instrument does not itself create enforcement machinery or penalties. Users should look to the Act, to the National Health Act 1953 where relevant, and to any other administrative instruments or operational policy documents administered by the Repatriation Commission for specifics on dispute resolution, recoveries, penalties, or enforcement processes. The instrument’s role is definitional and authorising rather than punitive.

This instrument is strictly a modifying instrument; its interaction with other laws is driven by explicit cross-references and by the definitions it imports.

• Made under the Act and authorised by s 18: The instrument is made under section 18 of the Act and explicitly states the Scheme is authorised by s 18 of the Act (clause 3; Schedule 1, item 2). Therefore the instrument’s legal effect derives from and is limited by the authority that section 18 of the Act confers on the Repatriation Commission.
• Imports eligibility from the Act: By defining "Eligible Person" to mean an eligible person within the meaning of the Act (Schedule 1, item 4), the instrument imports the Act’s substantive eligibility rules. The Scheme will operate only in respect of that population. Any interaction between scheme entitlements and the broader social security system is thereby mediated through the Act rather than through scheme-specific criteria.
• Cross-reference to the National Health Act 1953: Subsection 16A(9) is amended to replace "the Act" with "the National Health Act 1953" (Schedule 1, item 13). That change signals a specific point of statutory interaction with the National Health Act. Where subsection 16A(9) operates, it will now invoke the National Health Act rather than the Act for the matters addressed in that subsection.
• Treatment Principles modified elsewhere: The instrument defines "Treatment Principles" to mean the Treatment Principles as modified by a separate instrument, the Australian Participants in British Nuclear Tests and British Commonwealth Occupation Force (Treatment) (Modifications of the Treatment Principles) Instrument 2013 (Schedule 1, item 10). That creates an operational link to the 2013 modifications; implementers must consult that instrument to know what Treatment Principles apply.
• Terminology alignment with the Act: Several textual substitutions replace earlier scheme terms (for example "allowance") with the term "supplement" (Schedule 1, items 20-25). These substitutions indicate the Scheme now uses the Act’s vocabulary. That reduces the risk of internal inconsistency but makes the Scheme reliant on the Act for precise meaning of supplements and their interactions with other benefit systems.
• Repeal of prior instrument: The full repeal of the prior 2006 instrument (Schedule 2) means that the earlier instrument no longer operates. Any cross-references in other legislation to that earlier instrument may need re-evaluating; where the 2006 instrument was previously cited as an operative source, the new instrument supplants it for future matters, with transitional coverage for matters already started (Schedule 1, item 2B).
• Omitted content: The instrument omits various definitions and Part 5A (Schedule 1, items 3, 5, 7, 9, 11, 26). Where those terms were used in other instruments or statutes, users must trace the legal effect to the Act or other instruments. The instrument itself does not supply new procedural rules to replace omitted content, so the legal effect of those omissions will depend on other legislative materials.

Practically, the instrument’s interaction with other laws is one of dereferencing: it strips scheme-level, self-contained definitions and points implementers to the Act and to a small set of other instruments or statutes for substantive content. That creates a governance structure where the Act and the National Health Act, together with specified Treatment Principles instruments, will determine the detailed rights and obligations that the Scheme enables.

The instrument contains an internal amendment history confined to its own making and to the repeal of the prior instrument.

• Date of making, seal, and approval: The Repatriation Commission prepared and sealed the instrument on 8 June 2017 (front matter). The instrument was approved by the Minister for Veterans’ Affairs, Dan Tehan, on 23 June 2017 (front matter). The formal commencement date for the whole instrument was 1 July 2017 (clause 2(1)).
• Replaces sections 1A to 2 of the earlier instrument: Schedule 1 explicitly omits the existing sections 1A to 2 of the Repatriation Pharmaceutical Benefits Scheme and substitutes new provisions (Schedule 1, item 1). This is a direct textual replacement rather than a series of incremental edits.
• Multiple definition substitutions and omissions: Schedule 1 makes a series of definition changes in section 3, omitting several prior definitions and substituting a smaller set that align to the Act and to a referenced Treatment Principles instrument (Schedule 1, items 2-11). The schedule also omits several notes and a part (Schedule 1, items 12, 17-19, 26).
• Terminology amendments: Several provisions substitute "supplement" for "allowance" in section 23 and related paragraphs (Schedule 1, items 20-25), and other textual changes adjust cross-references (Schedule 1, items 13-16).
• Transitional provision: The instrument adds a transitional clause (2B) to preserve continuity for matters started under the 2006 instrument (Schedule 1, item 2B).
• Repeal effect: Schedule 2 repeals the prior Repatriation Pharmaceutical Benefits Scheme (Australian Participants in British Nuclear Tests) 2006 instrument in its entirety (Schedule 2, item 1). The instrument’s Note on commencement clarifies that the commencement table relates only to provisions as originally made and will not be amended to record later changes (clause 2, note).

This instrument is therefore a single consolidating rewrite and replacement of the earlier scheme instrument, implemented by express omission, substitution, and repeal rather than by incremental schedule amendments. The instrument does not record any later amendments in the text provided. Any post-2017 amendments would not be shown here.

The instrument itself contains no references to litigation, and the text does not identify any court or tribunal decisions relating to its provisions. The provided instrument records only administrative and formal details: the Repatriation Commission prepared and sealed it; the Minister approved it; and the commencement date is set for 1 July 2017 (prefatory clauses and clause 2). It does not list any judicial decisions, appeals, or legal challenges.

Consequently, based on the instrument as provided:

• There is no case law cited in the instrument.
• There are no references to disputes, judicial interpretation issues or litigation outcomes concerning this instrument recorded in the text supplied.
• Practitioners seeking litigation history or precedential interpretation of the redefined terms (for example what precisely constitutes an Eligible Person under the Act, or how the replacement of "allowance" with "supplement" affects entitlements) will have to consult court or tribunal databases and the parent Act, since the instrument itself does not record or summarise any adjudication.

In other words, the instrument does not contain litigation history. Any legal review that depends on judicial interpretation of the Act, the National Health Act 1953 (as cross-referenced), or the Treatment Principles instrument must proceed to those primary sources and to case reporters or tribunal records outside this instrument.

This instrument contains several drafting choices and transitional arrangements that create practical points of attention. The following are concrete items to watch for and to confirm in operational practice.

• Eligibility is imported from the Act. The definition of "Eligible Person" now points to the Act rather than supplying a scheme-level, self-contained test (Schedule 1, item 4). Practitioners must therefore check the Act for the precise eligibility criteria. Failure to do so may lead to incorrect determinations about who may receive pharmaceutical benefits under the Scheme.
• Removal of multiple prior definitions. The instrument omits numerous definitions (for example income support payment, MRCA supplement, pharmaceutical allowance, Repatriation Pharmaceutical Benefits Card, revoked scheme, RPBS) (Schedule 1, items 3, 5, 7, 9, 11). Where prior administrative practice relied on those definitions, implementers must map the old terms to the new legal framework. Do not assume the prior interpretation carries over automatically; the instrument’s omissions may change legal footing for particular entitlements.
• Single card definition replaces multiple card types. The instrument retains only "Repatriation Health Card ‑ For All Conditions" and deletes card types such as Repatriation Health Card ‑ For Specific Conditions and Repatriation Pharmaceutical Benefits Card (Schedule 1, items 6, 7). That changes the verification landscape. Systems that previously used more granular card types must adjust processes to accept either an identification card or a written authorisation as defined in the instrument.
• Terminology shift from "allowance" to "supplement". In s 23 the instrument substitutes "supplement" for "allowance" on several occasions (Schedule 1, items 20-25). Where other instruments, claims procedures or statutes refer to "allowance", implementers must not rely on out-of-date wording. The substitution may have substantive implications where eligibility or payment rights were tied to the old term.
• Cross-reference change to National Health Act 1953. Subsection 16A(9) is amended to substitute a reference to the National Health Act 1953 in place of "the Act" (Schedule 1, item 13). That is a narrow but potentially impactful redirection; it is necessary to check the context of subsection 16A(9) to determine the specific consequence of that change.
• Part 5A omitted. The instrument omits Part 5A (Schedule 1, item 26). The text supplied does not include the omitted Part’s former content. Consequently, users should not assume retained substantive protections or procedures previously located in Part 5A remain operative. Check the Act and supplementary instruments to reconstruct any administrative regimes formerly located there.
• Transitional clause only for "things started". Section 2B allows completion of "things started" under the 2006 instrument before 1 July 2017, but it applies only where an activity was started and not finished by that date (Schedule 1, item 2B). Parties that believed they had a completed entitlement under the old instrument but whose administrative process had not started prior to 1 July 2017 will not have that protection.
• No procedural detail in the instrument. The instrument authorises supply by Community Pharmacists but does not set claim procedures, reimbursement rates, record-keeping requirements or audit rules. Those operational details must be sought in the Act, in the National Health Act where invoked, or in separate administrative instruments. Failure to consult those sources risks non-compliance when making or processing claims.
• Repeal of the 2006 instrument in full. Schedule 2 repeals the earlier instrument entirely (Schedule 2, item 1). For historical entitlements or for matters that reference the 2006 instrument in other documents, careful reconciliation is necessary to ensure continuity is preserved where intended.

These are concrete operational attention points that arise directly from the instrument’s language. They point to areas where advisory attention, system updates, or procedural clarifications will be necessary to prevent entitlement, verification or claims-processing errors.

The instrument is short on operational detail. Compliance therefore means following the instrument’s definitional changes and using the Act and related instruments to supply detailed procedures. The following checklist sets out lawful steps and practical controls grounded in the instrument text.

1. Identify eligible persons using the Act

• Legal requirement: "Eligible Person means an eligible person within the meaning of the Act" (Schedule 1, item 4).
• Action: Obtain and apply the Act’s definition of eligible person to all claims and supplies. Do not rely on prior scheme-level tests. Maintain documentation of the legal source used to determine eligibility.

2. Accept the Repatriation Health Card ‑ For All Conditions or written authorisation as proof

• Legal source: The instrument defines this card as "an identification card, or written authorisation, provided to an Eligible Person in relation to treatment for all injuries or diseases" (Schedule 1, item 6).
• Action: Update dispensing and verification procedures so that pharmacists accept the card or a formal written authorisation. Ensure staff are trained to recognise the card and to record its details in dispensing records.

3. Understand supplier permissions

• Legal source: Section 2A enables Community Pharmacists to supply Pharmaceutical benefits to Eligible Persons (Schedule 1, item 2A).
• Action: Community Pharmacy operators should document internal policy reflecting that the Scheme authorises them to supply benefits to Eligible Persons. Where uncertain about claimability, refer to the Act and the Treatment Principles instrument referenced in the modified Scheme.

4. Update terminology and forms

• Legal source: The instrument substitutes "supplement" for "allowance" in several places (Schedule 1, items 20-25) and removes many prior definitions (Schedule 1, items 3, 5, 7, 9, 11).
• Action: Replace outdated references to "allowance" with "supplement" in internal forms, IT systems, reporting templates and communications. Remove references to card types no longer defined. Ensure coding and charting in pharmacy and scheme management systems reflect new terminology.

5. Preserve continuity for matters started under the old Scheme

• Legal source: Section 2B permits completion of things started under the 2006 instrument and not finished before 1 July 2017 (Schedule 1, item 2B).
• Action: Identify any open files, applications or claims that were started under the 2006 instrument and not completed by 1 July 2017. Record the start date and process the matter under the modified Scheme, treating it as if it had been started under the new Scheme.

6. Trace omitted content to the Act or other instruments

• Legal source: The instrument omits multiple definitions and Part 5A (Schedule 1, items 3, 5, 7, 9, 11, 26) and links to the Treatment Principles instrument 2013 (Schedule 1, item 10).
• Action: For each omitted definition or provision previously used in your operations, identify where that subject matter is now governed. Consult the Act, the National Health Act 1953 where relevant, and the Treatment Principles instrument referenced. Update policies to reflect the correct legal source.

7. Record retention and audit readiness

• Legal source: The instrument authorises supply and modifies identification documents but does not set record-keeping requirements in its text.
• Action: Retain dispensing and verification records that show compliance with the Scheme and with the Act. Ensure your files show the basis for eligibility, the Repatriation Health Card or written authorisation used, and any communications with administrators. Because enforcement provisions are not in the instrument itself, be prepared to produce records to the Repatriation Commission or other authorised bodies under the Act.

8. Coordinate with scheme administrators

• Legal source: The instrument is prepared by the Repatriation Commission and approved by the Minister (prefatory material and clause 3).
• Action: Liaise with the Repatriation Commission for operational guidance, claim submission systems, and any operational policies that interpret the Scheme. Request written guidance where necessary for areas not set out in the instrument, for example claim forms, reimbursement processes, and audit procedures.

9. Confirm interactions with other laws

• Legal source: Subsection 16A(9) is amended to refer to the National Health Act 1953 (Schedule 1, item 13).
• Action: Where s 16A(9) applies in your context, consult the National Health Act 1953 to determine applicable rules and obligations. Ensure your compliance program references both the Act and the National Health Act where the instrument points to them.

10. Legal review before changes to practice

• Recommendation grounded in the text: The instrument is primarily definitional and leaves procedural detail to other statutes and instruments.
• Action: Obtain a targeted legal review that maps prior scheme entitlements to the new framework, confirms eligibility tests under the Act, and checks whether previous processes that relied on omitted provisions require replacement policies.

Following these steps will align operational practice with the instrument’s legal changes. Because the instrument deliberately avoids procedural detail, practitioners must look beyond it to the Act, to the National Health Act 1953 where invoked, and to the Treatment Principles instrument noted in the Scheme for complete compliance procedures.